Literature DB >> 2335394

Reversal of multi-drug resistance in human KB cell lines by structural analogs of verapamil.

R Pirker1, G Keilhauer, M Raschack, C Lechner, H Ludwig.   

Abstract

Several structural analogs of verapamil were studied for their ability to reverse multi-drug resistance (MDR) in human KB cell lines. D595, D792 and verapamil completely reversed resistance to colchicine and adriamycin. D595 and D792 had a higher reversing potency than verapamil. Devapamil, gallopamil, emopamil and D528 partially reversed MDR. The reversing potency of a drug did not correlate with its calcium antagonistic activity. No differences in reversing potency between (R)-isomers, (L)-isomers and the racemic forms were observed in the case of both verapamil and emopamil. (R)-verapamil, which has less calcium antagonistic activity and less in vivo toxicity than racemic verapamil, and D792, which has higher reversing potency and less in vivo toxicity than racemic verapamil, should be suitable for clinical applications to overcome drug resistance in cancer patients.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2335394     DOI: 10.1002/ijc.2910450523

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  15 in total

1.  Verapamil sensitisation to alkaloids on colchicine-selected human colon adenocarcinoma cells.

Authors:  M J Ruiz Gómez; A Souviron; L Gil; M Martínez Morillo
Journal:  J Physiol Biochem       Date:  2001-12       Impact factor: 4.158

2.  Reversal of multidrug resistance by B859-35, a metabolite of B859-35, niguldipine, verapamil and nitrendipine.

Authors:  J Hofmann; A Wolf; M Spitaler; G Böck; J Drach; C Ludescher; H Grunicke
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

Review 3.  Structure and function of efflux pumps that confer resistance to drugs.

Authors:  M Ines Borges-Walmsley; Kenneth S McKeegan; Adrian R Walmsley
Journal:  Biochem J       Date:  2003-12-01       Impact factor: 3.857

Review 4.  P glycoprotein in human immunodeficiency virus type 1 infection and therapy.

Authors:  Sanjay U C Sankatsing; Jos H Beijnen; Alfred H Schinkel; Joep M A Lange; Jan M Prins
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

5.  Dexverapamil as resistance modifier in acute myeloid leukaemia.

Authors:  R Pirker; S Zöchbauer; H Kupper; A Lassmann; A Gsur; M Frass; G Krajnik; P Knöbl; K Lechner
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

6.  Dexverapamil to overcome epirubicin resistance in advanced breast cancer.

Authors:  B Thürlimann; N Kröger; J Greiner; K Mross; J Schüller; E Schernhammer; K Schumacher; G Gastl; J Hartlapp; H Kupper
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

7.  P-glycoprotein, glutathione and glutathione S-transferase increase in a colon carcinoma cell line by colchicine.

Authors:  M J Ruiz-Gómez; A Souviron; M Martínez-Morillo; L Gil
Journal:  J Physiol Biochem       Date:  2000-12       Impact factor: 4.158

8.  Reversal of anticancer multidrug resistance by the ardeemins.

Authors:  T C Chou; K M Depew; Y H Zheng; M L Safer; D Chan; B Helfrich; D Zatorska; A Zatorski; W Bornmann; S J Danishefsky
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-07       Impact factor: 11.205

Review 9.  P-glycoprotein-mediated multidrug resistance in normal and neoplastic hematopoietic cells.

Authors:  T Licht; I Pastan; M Gottesman; F Herrmann
Journal:  Ann Hematol       Date:  1994-10       Impact factor: 3.673

Review 10.  Pharmacologic circumvention of multidrug resistance.

Authors:  J M Ford; W N Hait
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.